Tanja D. De Gruijl

Reducing sialylation in melanoma increases classical pathway-mediated complement activation

Summary Based on the success in pre-clinical models, methods that reduce sialylation in tumors have progressed to clinical trials, as this improves anti-tumor cellular responses. Immune responses against cancer can also be mediated by soluble, non-cellular mechanisms, such as the...

In-human assessment of target engagement and blockade of radiolabeled BI 765063, an anti-SIRPα antibody

The signal regulatory protein alpha (SIRPα) receptor on myeloid cells binds cluster of differentiation (CD) antigen CD47 on tumor cells, resulting in a “don’t eat me” signal that inhibits phagocytosis. BI 765063, an anti-SIRPα antibody, may restore anti-tumor immunity by blocking...